In line with a 2015 stated goal, Episurf Medical announces that the milestone of 100 accounts approved and connected to the company’s proprietary μifidelity™ platform has been reached.
This information was published, 2016-01-25 08:00 CET (GLOBE NEWSWIRE) —
“I am delighted with this achievement especially considering that we have tightened the inclusion criteria for new accounts to ensure that surgeons can begin doing Episealer® procedures immediately, thereby driving account productivity. This performance indicates our direct sales strategy across the major European geographies is working and demonstrates an acceptance amongst surgeons to address the treatment gap between biologics and arthroplasty with a patient specific Episealer® implant“, says Rosemary Cunningham Thomas, CEO of Episurf Medical.
During 2016 Episurf Medical will continue to enlarge and strengthen its sales presence via an active recruitment process in Germany and the UK.
“I am confident that Episurf Medical’s expanding European footprint combined with growing patient demand for innovative cartilage treatments will drive accelerated surgical adoption of the Episealer® implant technology in 2016 and beyond. With five patient specific products in the portfolio including its first digital product, Epioscopy™, key sales managers in our main markets and a growing body of clinical evidence, Episurf Medical is well positioned to compete on a global scale in the years to come,” says Rosemary Cunningham Thomas.
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are in development for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system will enable implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention.
Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com. The information in this press release is such that Episurf Medical AB is required to disclose in accordance with the Securities Markets Act and/or the Financial Instruments Trading Act.
For more information, please contact:
Rosemary Cunningham Thomas, CEO, Episurf Medical
Tel: +46 (0) 70-7655892
Tel: +44 (0) 7803-753603